Pinned
We’ve raised $400M at a $3.8B valuation to further advance AI-driven molecular design. The round was led by @IndexVentures, alongside @kleinerperkins, @sequoia, @_DimensionCap, and others.
Chai Discovery
@chaidiscovery
- We started Chai with a mission to enable the next generation of breakthrough medicines. Hear our co-founders @joshim5 and @Mattmcpartlon1 talk to @gradypb on @sequoia's Training Data to talk about the future of AI drug design. Full episode below.To date, finding a drug has been a process of guess & check… screening millions of molecules hoping one binds. @chaidiscovery is changing the paradigm… describe the molecule you want, and the model designs it. @joshim5 and @Mattmcpartlon1 took antibody hit rates from roughly
- We’re delighted to announce our third agreement this week, this time a collaboration with @argenxglobal. argenx has built one of biotechnology’s most productive antibody engines. We’ll be putting Chai’s frontier molecular design platform into the hands of their scientists.
- We’re delighted to announce a collaboration with @pfizer to accelerate their drug discovery efforts. Pfizer will deploy our latest frontier AI model Chai-3 and a custom model leveraging Pfizer's proprietary data and tailored to their workflows. Chai-3 shows step-change
- Thank you to Forbes for the recognition!2026 #ForbesAI50 Artificial intelligence has become part of our lives, increasingly core to how we work, search for information and express ideas. In the last year, the startups spearheading this paradigm shift have raised gobs of money from venture firms to build applications
